TABLE 2.
Comparison between patients with negative vs positive serologic response to coronavirus disease 2019 vaccination, according to the cutoff point of 50 AU/mL
| Serologic response | Negative (n = 14) | Positive (n = 24) | P |
|---|---|---|---|
| Age, mean ± SD (y) | 17.9 ± 2.6 | 19.1 ± 2.9 | 0.21 |
| Males, n (%) | 7 (50) | 18 (75) | 0.16 |
| Type of transplantation | |||
| Second transplantation, n (%) | 3 (21) | 1 (4) | 0.13 |
| Multiple organ transplantations, n (%) | 0 | 2 (8)a | |
| Living related, n (%) | 6 (43) | 10 (42) | |
| Living unrelated, n (%) | 3 (21) | 4 (17) | |
| Deceased donor, n (%) | 5 (36) | 10 (42) | |
| Time from transplantation to serologic testing, mean ± SD (y) | 5.9 ± 5.2 | 8.2 ± 5.8 | 0.23 |
| Time from second vaccine to serologic testing, median (IQR) (d) | 24.5 (15–40) | 46 (27–56) | 0.05 |
| Prevaccine medications and labs | |||
| Tacrolimus trough levels, mean ± SD (ng/mL) | 7.4 ± 2 | 6.5 ± 1.9 | 0.17 |
| Mycophenolate dose, mean ± SD (mg/m2/dose) | 365 ± 69 | 324 ± 113b | 0.24 |
| Rituximab treatment, n (%) | 7 (50) | 2 (8) | 0.01 |
| ATG treatment, n (%) | 3 (21) | 2 (8) | 0.34 |
| eGFR, mean ± SD (mL/min/1.73m2) | 53.3 ± 28.5 | 59.8 ± 17.7 | 0.39 |
| eGFR <30 mL/min/1.73m2, n (%) | 4 (29) | 0 (0) | 0.014 |
| IgG levels, mean ± SD (mg/dL) | 877.5 ± 377 | 1078.9 ± 367.5c | 0.12 |
| WBC count, mean ± SD (K/mL) | 6.33 ± 1.31 | 7.09 ± 2.34 | 0.27 |
aOne patient with kidney and liver transplant and another with kidney and lung transplant.
bTwo patients were on azathioprine.
cIgG levels were obtained for 21 of 24 patients.
ATG, anti-thymocyte globulin; AU, antibody unit; eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; IQR, interquartile range; K, thousands; WBC, white blood cell.